Keros Therapeutics, Inc. (KROS) AI Stock Analysis

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing novel treatments for patients grappling with hematological and musculoskeletal disorders characterized by significant unmet medical needs. At the forefront of its pipeline is KER-050, a lead protein therapeutic designed to address low blood cell counts in conditions like myelodysplastic syndromes and myelofibrosis. In addition to protein-based therapies, Keros is progressing KER-047, a small molecule compound in Phase 1 clinical trials for anemia. The company is also exploring KER-012 in Phase 1 trials for bone loss conditions, such as osteoporosis and osteogenesis imperfecta, and pulmonary arterial hypertension. Founded in 2015, Keros is headquartered in Lexington, Massachusetts.

Annual revenue rose from $20.1M in FY2021 to $244.1M in FY2025, reflecting a 5-year revenue CAGR of 150.0%. After reporting net losses of -$58.7M in FY2021, -$104.7M in FY2022, -$153.0M in FY2023, and -$187.4M in FY2024, Keros delivered net income of $87.0M in FY2025 with an operating margin of 28.9%. Research and development expense was $129.6M in FY2025. Over the trailing twelve months, revenue was $15.0M with EPS of -$3.22 and an operating margin of -655.8%. In the latest quarter ended June 30, 2026, quarterly revenue declined 99.8% year-over-year.

As of June 30, 2026, Keros held $257.6M in cash and short-term investments against $15.7M in total debt, resulting in net cash of $241.9M. Total assets were $287.6M and shareholders' equity was $262.3M, yielding a debt-to-equity ratio of 0.06 and a current ratio of 21.96. Operating cash flow in FY2025 was $107.5M and free cash flow was $106.0M. In FY2025, capital expenditures were $1.6M and share buybacks totaled $375.0M, with the share count declining 15.5% over 5 years.

Keros trades at a market capitalization of $211.4M and an enterprise value of -$11.3M. Its forward P/E multiple is 48.8x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio is 14.1x versus the peer median of 4.1x, while its price-to-book ratio is 0.9x. Over the past year, KROS shares dropped 22.4%, compared to a 16.8% gain for the S&P 500 (SPY). Over a 5-year period, KROS declined 72.7% while the S&P 500 gained 83.0%.

Keros has 4 Strong Buy ratings and 3 Hold ratings, with zero Buy, Sell, or Strong Sell recommendations. The mean price target of $19.83 represents an 86.1% premium over the last close of $10.66. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $15.6M and an EPS of -$5.22. For the following fiscal year, 5 analysts project revenue of $13.7M and an EPS of -$6.62. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Keros Therapeutics, Inc. (KROS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KROS income statement, KROS balance sheet, KROS key metrics, KROS analyst forecast, KROS chart. See the KROS stock overview for the latest quote and news.